Search

everythinglearnresearchcommunity

for

Search:↓

Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.

Ritlecitinib is effective and safe for long-term treatment of alopecia areata.

Ruxolitinib helped a patient with alopecia areata regrow hair.

Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.

Topical ruxolitinib and oral minoxidil together can regrow hair in certain types of hair loss.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

New JAK inhibitor drugs show promise for treating skin diseases but need more research on safety and effectiveness.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.

Baricitinib shows promise for treating alopecia areata with mild side effects.

Oral difelikefalin significantly reduces itch in notalgia paresthetica.

JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.

Lack of KSR1 stops certain skin tumors in mice.

Baricitinib successfully regrew hair in an 8-year-old boy with alopecia totalis linked to a KRT74 gene variant.

PI3Kδ inhibition may effectively treat cutaneous chronic graft-versus-host disease.

JAK inhibitors show promise in treating difficult skin diseases.

Deucravacitinib led to full hair regrowth in a severe alopecia areata patient.

Many drugs can cause lipid metabolism issues, and labels need better warnings.

Rezpegaldesleukin shows promise for treating severe alopecia areata.

ACKR2 helps prevent skin scarring and hair loss by controlling inflammation.

Topical ruxolitinib cream may help treat frontal fibrosing alopecia.

No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.

Nilotinib can cause generalized keratosis pilaris.

Finasteride helps female-pattern hair loss.

JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.

Entospletinib effectively prevents eye and skin GVHD in mice.